戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 re chemical ionization (APCI; e.g., 1 pg for reserpine).
2 a key intermediate previously transformed to reserpine.
3 (10 micro M) as well as by pretreatment with reserpine.
4 be partially overcome by the ABCG2 inhibitor reserpine.
5 ter was reduced to 5.8 by the VMAT inhibitor reserpine.
6 ression with VMAT2, and this was reversed by reserpine.
7 dded carboxyls, generates a binding site for reserpine.
8 nsporter-mediated storage into vesicles with reserpine.
9 ed extracellular Ca2+, and were abolished by reserpine.
10 likely explains the diminished release after reserpine.
11  efflux is supressed by an inhibitor of Blt, reserpine.
12 f Bmr can be inhibited by the plant alkaloid reserpine.
13 g injections of the monoamine-depleting drug reserpine.
14 nt amphetamine and the antihypertensive drug reserpine.
15 ar monoamine transporter-2 with Ro-4-1284 or reserpine.
16 mportant 3 R MIAs and spirooxindoles such as reserpine.
17 oxidation products of the benchmark compound reserpine.
18 the vesicular monoamine transport inhibitor, reserpine.
19 l threshold and resistance to the effects of reserpine.
20 creases in tracer uptake with propranolol or reserpine.
21 ) or a triple therapy (hydralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlorothiazide 3 mg/d [HRH
22 th a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed.
23 weanling rats were given daily injections of reserpine (1 mg/kg, i.p.) or vehicle on postnatal day (P
24 normal conditions and following five days of reserpine (1 mg/kg/day), a treatment that causes a break
25 ministration of the dopamine-depleting agent reserpine (10 mg/kg) induces Fos expression in striatopa
26 ng by [125I]IAPEGlyMER was blocked by 100 nM reserpine, 10 microM tetrabenazine, 1 mM serotonin, and
27                Pre-treatment with 10.0 mg/kg reserpine (18 h prior to AMPH or MDMA) attenuated dopami
28 he landmark syntheses of morphine (1952) and reserpine (1956) by Gates and Woodward, respectively, th
29                                 In contrast, reserpine (20 and 40 mg/L) did not evoke overt acute beh
30 er halothane anaesthesia), pretreatment with reserpine (4 mg/kg, i.p., 24 h beforehand), unilateral p
31 hibition was stereospecific and sensitive to reserpine (50 nM), which blocks VMAT1 and VMAT2, but res
32 howed IC50 values of approximately 37 nM for reserpine, 83 nM for AIPPMER, 200 nM for IAPEGlyMER, and
33                                      Because reserpine (a VMAT inhibitor) can precipitate depressive-
34             Experimental treatments in which reserpine, a known inhibitor of dopamine in Drosophila,
35 rt is inhibited by the competitive inhibitor reserpine, a second-line agent to treat hypertension, an
36              We found that administration of reserpine, a small-molecule inhibitor of the vesicular m
37                      Cells were treated with reserpine, a vesicular monoamine transport blocker that
38                                              Reserpine, a vesicular monoamine transporter inhibitor,
39 chondrial Ca(2+) pools did not eliminate the reserpine-activated release.
40                                              Reserpine activation of endogenous processing enzymes wa
41                                              Reserpine also improved photoreceptors in retinal organo
42                                              Reserpine (an inhibitor of efflux pumps) reduced the eff
43 r polypeptide, which was blocked by 1 microM reserpine and 10 microM tetrabenazine.
44 distribution was modulated by treatment with reserpine and amitriptyline.
45 most drug treatments but was up-regulated by reserpine and clotrimazole.
46  examined the acute and long-term effects of reserpine and d-amphetamine on zebrafish behavior in the
47                                              Reserpine and ketanserin are slightly more potent inhibi
48           Two iodophenylazide derivatives of reserpine and one iodophenylazide derivative of tetraben
49  In a separate group of rats, the effects of reserpine and reserpine+heat on dopamine synthesis were
50 of isotopic peak clusters in mass spectra of reserpine and substance P are measured using Fourier tra
51            Subcellular studies revealed that reserpine and tetrabenazine at concentrations near their
52 s strongly attenuated by inhibitors of VMAT (reserpine and tetrabenazine) and DAT (GBR12909 and rimca
53  decreased following 15-min incubations with reserpine and tetrabenazine, as evidenced by a decrease
54  yohimbine, the noradrenaline-depleting drug reserpine and the adrenergic neuron-blocking agent guane
55 of tunicamycin resistance in the presence of reserpine and the survival ability of the tet38 overexpr
56                                              Reserpine and verapamil blocked [3H]putrescine uptake in
57 e test mix-composed of aspartame, cortisone, reserpine, and dioctyl phthalate has been developed to a
58 ing rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole.
59 emonstrated by studying the effects of EGTA, reserpine, and prolonged stimulation by K(+).
60           Sf9 vesicles expressing VMAT2 show reserpine- and tetrabenazine-protectable photolabeling b
61 selective synthesis of the well-known target reserpine are described, culminating in a total synthesi
62 aches to the construction of the DE rings of reserpine are reported.
63 dient plates containing both a substrate and reserpine as an efflux pump inhibitor.
64 overed two drug combinations, remdesivir and reserpine as well as remdesivir and IQ-1S, which display
65 TQ-Orbitrap-MS to detect the distribution of reserpine at 2 h post a 20 mg/kg oral dose.
66                Pre-treatment with 10.0 mg/kg reserpine attenuated dopamine and serotonin release indu
67                                              Reserpine binding captures a cytoplasmic-open conformati
68 kably, however, this mutant displayed normal reserpine binding that remained coupled to DeltaH+, but
69  and reduced ability of serotonin to inhibit reserpine binding, suggesting that although not required
70  to DeltaH+, but serotonin failed to inhibit reserpine binding, suggesting that the charge reversal s
71                                 By contrast, reserpine binds in a cytoplasm-facing conformation, expa
72 d binding of two potent inhibitors of VMAT2: reserpine binds the cytoplasm-facing conformation, and t
73                  Although cyclosporine A and reserpine blocked calcein-AM transport by MDR1, these dr
74 ore, transient exposure to tetrabenazine and reserpine, but not methyl reserpate and reserpic acid, i
75  strictosidine synthase cluster, whereas the reserpine cluster arose later.
76 sacrifice), was greater in rats treated with reserpine compared to controls; heating the reserpinized
77          Pharmacologic inhibition of ICBT by reserpine compensated for CH25H loss, elicited angiostat
78 ensitivity was restored by the Pgp inhibitor reserpine, demonstrating that only drug retention was th
79                                              Reserpine depletes monoamines, and causes depression and
80                             In contrast, two reserpine derivatives, methyl reserpate and reserpic aci
81                                              Reserpine did not disrupt the ability of 1 microM KN-93
82 d that the vesicular amine transport blocker reserpine does not block amphetamine-induced release.
83 otted analytes, exemplified by tamoxifen and reserpine, during analysis by DESI-MS was studied.
84                       We found that 1 microM reserpine for 90 min reduced stimulation-dependent dopam
85  not significantly different from either the reserpine group (not heated) or the AMPH or MDMA alone g
86 G uptake in BAT, whereas the propranolol and reserpine groups showed only faint to mild (18)F-FDG upt
87 = iodovinyltetrabenazine > ketanserin > or = reserpine > haloperidol > GBR 12909) consistent with the
88 ization developed for the total synthesis of reserpine has been explored by both experiment and theor
89             L-3,4-dihydroxyphenylalanine and reserpine have been used to increase and decrease, respe
90  group of rats, the effects of reserpine and reserpine+heat on dopamine synthesis were measured.
91 MDMA-induced dopamine release observed after reserpine; however, AMPH or MDMA dependence upon vesicul
92 specific triple antihypertensive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drink
93 Furth rats) being treated with a hydralazine-reserpine-hydrochlorothiazide regimen.
94      Myocardial catecholamine depletion with reserpine in 2 hearts also abolished changes in MAPD and
95 markedly increased by L-DOPA or decreased by reserpine in a time-dependent manner in response to in v
96 normal cells by TEV and argue for the use of reserpine in adjuvant melanoma therapy.
97    RPHPLC analysis confirmed the presence of reserpine in bacterial metabolites when compared to a st
98 e oxidation of 3,4-dihydroxybenzoic acid and reserpine in negative ion mode and by the reduction of t
99 e to "turn on" essentially 100% oxidation of reserpine in this flow rate range.
100 ermine that l-3,4-dihydroxyphenylalanine and reserpine increase and decrease, respectively, the volum
101 th pargyline, a monoamine oxidase inhibitor, reserpine increased catecholamine levels in the cytosol
102 llar norepinephrine levels by treatment with reserpine increased Purkinje cell GAD67 mRNA levels (250
103 ve Transporter Interactions class (including reserpine, indapamide, digoxin, and deslanoside) has sta
104 splenic nerve and catecholamine depletion by reserpine indicate that these nerves are catecholaminerg
105                                              Reserpine induced a rise in intracellular Ca(2+), as det
106                                              Reserpine induced changes in the sleep architecture with
107  study of altered central pain processing in reserpine induced myalgia.
108  decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats.
109 th this, PHCCC produced a marked reversal of reserpine-induced akinesia in rats.
110 l-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamin
111     MMP-2200 had no effect in preventing the reserpine-induced akinesia, nor did it affect locomotion
112 aloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHD
113 mine D2/3 receptor agonist RU 24213 reversed reserpine-induced akinesia, yet paradoxically increased
114 post-treatment period partially reversed the reserpine-induced attenuation of dopamine release.
115       The dopamine precursor L-DOPA reversed reserpine-induced bradykinesia without restoring fast do
116                                          The reserpine-induced myalgia (RIM) model lowers pain thresh
117 reserpine is thought to be counteracted by a reserpine-induced replenishment of stores.
118                      Acute administration of reserpine induces Fos expression in striatopallidal neur
119 tions in the catalase-peroxidase gene and to reserpine-inhibitable efflux pumps.
120 mpathetic neurotransmitters (guanethidine or reserpine) inhibited capsaicin-evoked iCGRP release.
121 06 of Bmr not only reduce its sensitivity to reserpine inhibition but also significantly change its s
122      The multidrug resistance pump inhibitor reserpine inhibits resistance to ethidium bromide in bot
123  further combined with the SRM transition of reserpine (internal standard) and eight probe substrates
124  AMPH or MDMA-induced transmitter release by reserpine is thought to be counteracted by a reserpine-i
125 om vesicles to the cytoplasm by the use of a reserpine-like compound, Ro4-1284, does not increase ext
126 ats administered urethane anesthesia and the reserpine-like compound, RO4-1284.
127 re treated either acutely or repeatedly with reserpine (low dopaminergic tone) or vehicle (high dopam
128                                  Conversely, reserpine-mediated dopamine depletion or blockade of dop
129  scopolamine (50 mg/kg) partially attenuates reserpine-mediated striatal Fos expression.
130 NMDA antagonists (+)MK-801 or CPP attenuated reserpine-mediated striatal Fos induction whereas pretre
131 t models of neuropathic pain as well as in a reserpine model of central pain.
132 ress this paradox, we examined the effect of reserpine on amphetamine-induced dopamine release from p
133 sensitivity, suggesting that effects of VMAT/reserpine on sleep are mediated by multiple monoamines.
134 imit of detection in the range of 100 nM for reserpine or better than 5 nM for verapamil in aqueous s
135  by > 95% compared with cells not exposed to reserpine or by 75% compared with reserpine-treated cult
136 rug tetrabenazine, the antihypertensive drug reserpine or the substrate serotonin.
137 ne-based anesthesia) were given propranolol, reserpine, or diazepam intraperitoneally before (18)F-FD
138 e VMAT mutants are consistently resistant to reserpine, other aspects of their sleep phenotype are de
139 rking electrode potential, it was found that reserpine oxidation could be "turned off" at flow rates
140 0% of the control level after propranolol or reserpine (P < 0.05).
141                                              Reserpine partially restored the balance between autopha
142 ) or following dopamine depletion induced by reserpine plus alpha-methyl-para-tyrosine pretreatment.
143                                              Reserpine pre-treatment caused reductions in core body t
144                                              Reserpine pretreated rat hearts also showed significant
145                                           In reserpine-pretreated adult and young rats, however, part
146 mulation of monoamine-depleted ganglia (from reserpine-pretreated rats, 3 mg kg-1 for 24 h) failed to
147                                              Reserpine pretreatment did not affect amphetamine-mediat
148  state of low dopaminergic tone (i.e., after reserpine pretreatment).
149 l antagonist-like effects even 20 days after reserpine pretreatment.
150  12, 16, 20, or 24 days (Experiment 2) after reserpine pretreatment.
151 utoreceptors, until long after conclusion of reserpine pretreatment.
152 r activity for only the initial 2 days after reserpine pretreatment.
153 or the vesicular monoamine transport blocker reserpine prevented drug-induced free radical formation.
154                      In animals treated with reserpine, profound akinesia was induced that was revers
155                                 In parallel, reserpine reduced amphetamine-induced dopamine release b
156               Blocking vesicular uptake with reserpine reduced the initial uptake rates of PHEN and D
157 ed 5 h or 1, 2, 4, or 8 days after the 5-day reserpine regimen.
158 ion limit of 8 and 25 fmol for verapamil and reserpine, respectively, and quantitation capabilities w
159 lation of transcription was more modest, and reserpine responses were only incompletely blocked by ch
160                           The pump inhibitor reserpine reversed both tolerance to INH and resistance
161  pesticides, pharmaceuticals and explosives (reserpine, roxithromycin, propazine, prochloraz, spinosa
162                 It was not stereospecific or reserpine sensitive, but was correlated with hydrophobic
163               Treatment with L-DOPA produced reserpine-sensitive dissipation of the electron-dense ag
164 es in the VTA may have greater potential for reserpine-sensitive storage and release of dopamine than
165 ing single monoamine pathways did not affect reserpine sensitivity, suggesting that effects of VMAT/r
166                               Treatment with reserpine significantly decreased the swimming induced p
167                             When a series of reserpine solutions (0.5, 1.0, 5.0, and 10.0 microM) wer
168                                     Standard reserpine solutions of varying concentration were electr
169 ; either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be added (n = 2365); or placebo
170                   Uptake blockade by DMI and reserpine suggest that uptake and storage of 11C-EPI app
171 ar monoamine transporter-2 (VMAT2) inhibitor reserpine, suggesting a dependence on the vesicular DA s
172 S Food and Drug Administration-approved drug reserpine suppressed lactate-mediated HCAR1 activation,
173                   An anti-hypertensive drug, reserpine, suppressed TEV uptake and disrupted TEV-induc
174                                  Relative to reserpine, the flavonoids exhibited narrower linear dyna
175               When WT mice were treated with reserpine to deplete adrenergic neurotransmitters from s
176 -dependent dopamine release, we administered reserpine to saline- and amphetamine-pretreated rats 1 d
177 ls that received apomorphine compared to non-reserpine treated animals, reflecting the well described
178 uts of glutamate and aspartate in the EPN of reserpine-treated and normal individuals, whilst the dop
179 exposed to reserpine or by 75% compared with reserpine-treated cultures.
180                                    In DD and reserpine-treated mice, quinpirole decreased destaining
181 reparations from dopamine-deficient (DD) and reserpine-treated mice.
182                                              Reserpine-treated patient organoids revealed modulation
183 6-OHDA)-treated rat and 2) locomotion in the reserpine-treated rat.
184 differential display in the adrenal gland of reserpine-treated rats and then isolated two transcripts
185  the substantia nigra and corpus striatum of reserpine-treated rats.
186                                       In DD, reserpine-treated, and control mice, exposure to the D2-
187 ing exposure to cold and that propranolol or reserpine treatment can remarkably reduce the high (18)F
188                                              Reserpine treatment increased both CPE and PC activity i
189      Forskolin stimulation of PC12 cells and reserpine treatment of rats increased, in nuclear extrac
190 sm of this effect, we examined the effect of reserpine treatment on the activities of three different
191 unable to elicit Fos even following repeated reserpine treatment).
192                                    Following reserpine treatment, stimulation of either D1 or D2 rece
193 he respective mass spectra of model compound reserpine, under various operating conditions to better
194 t potentials and detect host-origin compound reserpine using Reverse Phase High-Performance Liquid Ch
195 combination of altanserin (5HTR2 inhibitor), reserpine (VMAT inhibitor), and VP16-XlCreb1 (constituti
196        Following 3 days of basal recordings, reserpine was administered on three consecutive days to
197                                              Reserpine was relatively easy to oxidize (E(p) = 0.73 V
198 lls with the catecholamine transport blocker reserpine was shown previously to increase enkephalin le
199              Pulsed-pressurized injection of reserpine was used to experimentally simulate narrower p
200 ea that VMAT is the sleep-relevant target of reserpine, we found that VMAT-null mutants have an incre
201         The effect of L-DOPA was reversed by reserpine, which inhibits the amine-proton exchangers VM
202         Release was reduced upon exposure to reserpine, which inhibits vesicular packaging.
203 emistry was tested using the indole alkaloid reserpine, which is often used to test the specification
204 c positive hits, including the lead molecule reserpine, which maintained photoreceptor development an

 
Page Top